Trust Co. of Oklahoma Buys 177 Shares of Novartis AG (NYSE:NVS)

Trust Co. of Oklahoma boosted its stake in shares of Novartis AG (NYSE:NVS) by 1.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,898 shares of the company’s stock after purchasing an additional 177 shares during the quarter. Trust Co. of Oklahoma’s holdings in Novartis were worth $1,158,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVS. Janney Montgomery Scott LLC grew its stake in Novartis by 1.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 249,622 shares of the company’s stock valued at $24,291,000 after buying an additional 4,624 shares during the last quarter. Marino Stram & Associates LLC boosted its holdings in Novartis by 4.5% during the fourth quarter. Marino Stram & Associates LLC now owns 4,642 shares of the company’s stock valued at $452,000 after acquiring an additional 200 shares during the period. Daymark Wealth Partners LLC grew its position in shares of Novartis by 5.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 29,272 shares of the company’s stock valued at $2,848,000 after purchasing an additional 1,395 shares during the last quarter. XML Financial LLC increased its stake in shares of Novartis by 6.7% in the fourth quarter. XML Financial LLC now owns 10,455 shares of the company’s stock worth $1,017,000 after purchasing an additional 656 shares during the period. Finally, Nisa Investment Advisors LLC lifted its position in shares of Novartis by 95.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,022 shares of the company’s stock worth $99,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 1.6 %

Shares of NVS stock opened at $98.17 on Thursday. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The stock has a fifty day moving average price of $100.22 and a 200 day moving average price of $108.81. The stock has a market cap of $200.65 billion, a P/E ratio of 11.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.57.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the business earned $1.74 EPS. Analysts predict that Novartis AG will post 7.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on NVS shares. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to data from MarketBeat.com, Novartis presently has an average rating of “Hold” and an average target price of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.